When it comes to IQVIA (formerly IMS) drug database, do you really know about this database? How about its after-sales service? And is it really worth your purchase? Today, I am going to analyze IQVIA (formerly IMS) drug database's product composition, data, application scenarios, updates, strengths and weaknesses, price, value-added services, social evaluation, and other dimensions of multi-dimensional analysis to help you have a new understanding of it.
In order to facilitate a more intuitive understanding of the IQVIA (formerly IMS) drug database, I introduced a pharnexcloud database, which has a wide coverage of domestic customers, as a comparison.
1. Product Composition
IQVIA (former IMS) pharmaceutical database: It consists of three major sections: business consulting, drug research and development, and comprehensive services.
Pharnexcloud: 10 sections including drug research and development, listed drugs, drug sales, market information, consistency evaluation, APIs, medical devices, production and inspection, rational use of drugs, and medical literature.
2. Data sources
Both involve thousands of data sources in the collection of data sources, including but not limited to (①Pharmaceutical Intelligence: Laboratory research, internal meetings, professional reports, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific and technological journals, literature, etc.). ② Pharmaceutical database: heterogeneous resources, based on cloud computing, cloud storage, pharmaceutical big data processing, etc.. (iii) Pharmaceutical data: countries or regions around the world, information, corporate reports, medical meetings, news information, investor pressure, company annual reports, health care, pharmaceutical companies, medical journals, other resources, etc.).
3 Data display results
We will IQVIA database in the country's most handful of data (China Hospital Pharmaceutical Statistics Report CHPA ) and pharnexcloud's (national hospital sales data) an intuitive comparison
IQVIA database (China Hospital Pharmaceutical Statistics Report), based on the overall 9454 hospitals ( ≥100 beds) for sample design, the sample covers 255 cities. There are only about 1,000 hospitals in the sample, and the total number that can be extrapolated is about 8,000.
IQVIA database global pharmaceutical transaction information by more than 80,000;
pharnexcloud database (national hospital sales data), this database is based on 10,000 hospitals (second-level and above hospitals) for the sample design, covering the country's 24 provinces and all the key cities and regions and stratified sampling of more than 2,200, through a professional Through the professional calculation model stratified amplification, the sample hospitals can be projected to more than 9,000. This is a scale of coverage unmatched by other databases at home and abroad.
pharnexcloud database of global pharmaceutical transaction information 19,653 (I do not have enough authority, can only check the data from 2021 to date), it can be inferred that pharnexcloud in the global pharmaceutical transaction information data is also higher than the IQVIA database.
And the value-added services are: ① Specialized docking demand, one-on-one guidance, professional team to solve industry data problems. ② Salon, lecture tour, summit, project trading, demand docking and other activities to support, VIP to join their drug fusion circle ecosystem (currently doing very well in the country's pharmaceutical networking circle).
The author said more useless, mainly with their own point of demand for pharmaceutical databases, personal trial comparison in order to make the optimal decision.